This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail.

Koskela, Essi V.; de Ruijter, Jorg C.; Frey, Alexander D.

Following nature's roadmap

Published in:
BIOTECHNOLOGY JOURNAL

DOI:
[10.1002/biot.201600631](https://doi.org/10.1002/biot.201600631)

Published: 01/08/2017

Document Version
Peer reviewed version

Published under the following license:
CC BY

Please cite the original version:
Koskela, E. V., de Ruijter, J. C., & Frey, A. D. (2017). Following nature's roadmap: folding factors from plasma cells led to improvements in antibody secretion in *S. cerevisiae*. *BIOTECHNOLOGY JOURNAL*, 12(8), [1600631]. <https://doi.org/10.1002/biot.201600631>

This material is protected by copyright and other intellectual property rights, and duplication or sale of all or part of any of the repository collections is not permitted, except that material may be duplicated by you for your research use or educational purposes in electronic or print form. You must obtain permission for any other use. Electronic or print copies may not be offered, whether for sale or otherwise to anyone who is not an authorised user.

Research Article

Following nature's roadmap: folding factors from plasma cells led to improvements in antibody secretion in *S. cerevisiae*

Essi V Koskela¹

Jorg C de Ruijter^{1, 2}

Alexander D Frey¹

¹ Department of Bioproducts and Biosystems, Aalto University, Espoo, Finland

² current address: Department of Biocatalysis and Isotope Chemistry, Almac Sciences, Craigavon Northern Ireland, United Kingdom

Correspondence: Dr. Alexander D Frey, Bioproducts and Biosystems, Aalto University, Kemistintie 1, 02150 Espoo, Finland.

E-mail: alexander.frey@aalto.fi

Keywords: Synthetic biology, yeast, antibodies, protein folding

Abbreviations: **PDI**, protein disulfide isomerase; **PPIase**, peptidyl-prolyl *cis-trans* isomerase

1 **Abstract**

2 Therapeutic protein production in yeast is a reality in industry with an untapped potential to expand
3 to more complex proteins, such as full-length antibodies. Despite multiple numerous engineering
4 approaches, cellular limitations are preventing the use of *Saccharomyces cerevisiae* as the titers of
5 recombinant antibodies are currently not competitive. Instead of a host specific approach, we
6 demonstrate the possibility of adopting the features from native producers of antibodies, plasma
7 cells, to improve antibody production in yeast. We selected a subset of mammalian folding factors
8 upregulated in plasma cells for expression in yeast and screened for beneficial effects on antibody
9 secretion using a high-throughput ELISA platform. Co-expression of the mammalian chaperone
10 BiP, the co-chaperone GRP170, or the peptidyl-prolyl isomerase FKBP2, with the antibody
11 improved specific product yields up to two-fold. By comparing strains expressing FKBP2 or the
12 yeast PPIase Cpr5p, we demonstrate that speeding up peptidyl-prolyl isomerization by
13 upregulation of catalyzing enzymes is a key factor to improve antibody titers in yeast. Our findings
14 show that following the route of plasma cells can improve product titers and contribute to
15 developing an alternative yeast-based antibody factory.

1 Introduction

Antibodies are sophisticated agents of the mammalian immune system to fight against foreign pathogens and neoplastic tissue. In addition to their established use in diagnostics and research, antibodies, and especially IgG molecules, are used as advanced human therapeutics [1]. One of the main limitations in their use as a treatment is their high cost of production, as therapeutic antibodies are most often expressed in mammalian cell lines such as CHO cells. Due to ease of manipulation and cultivation, also lower eukaryotes such as yeasts have been considered as an alternative for production of recombinant antibodies [2–4]. However, obtaining the target glycoform of the antibody is crucial for the therapeutic and clinical efficacy. Yeasts typically produce hypermannosylated glycoproteins, which is a clear hindrance for therapeutic glycoprotein production for human use. Although glycoengineering of yeasts has greatly advanced during recent years [5–7], glycan structures are not the only hurdle for obtaining significant yields of full-length IgG molecules for therapeutic applications. Especially in the case of *Saccharomyces cerevisiae* product titers have remained modest, for example due to inefficient folding or proteolytic processing [8–10]. Despite the fact that commercial production of therapeutic proteins such as insulin in *S. cerevisiae* is practiced [11], transforming yeast cells into an antibody factory requires extensive cellular engineering to improve target protein yields.

The roadmap for antibody production with high efficiency is already explicated by nature: studies of how the immune system's B cells differentiate into antibody-secreting plasma cells provide a comprehensive blueprint of the factors needed to equip the cell for complex protein production. The most striking feature of these professional secretors is their extensive endoplasmic reticulum (ER), which fills most of the cytoplasm. Accordingly, many of the biochemical activities of the

ER are upregulated during differentiation, including the abundance of folding factors, such as chaperones, co-chaperones, protein disulfide isomerases (PDIs), and peptidyl-prolyl isomerases (PPIases) [12–14]. Overexpression of folding factors, most notably PDI and the chaperone BiP, have been studied in recombinant protein production for over two decades in different expression systems amongst others including yeasts, insect cells and mammalian cells [15–19]. In the case of antibody production in *S. cerevisiae*, overexpressing PDI (Pdi1p) and BiP (Kar2p), and ER engineering have been effective strategies in several occasions [8, 9, 20].

Previously, we demonstrated that following the example of plasma cells by increasing the size of ER prior to protein expression, through deletion of the lipid regulator gene *OPII*, is beneficial for antibody production in *S. cerevisiae* [9]. Mimicking steps in B cell differentiation has been proposed as an engineering strategy for mammalian cell platforms and interestingly, in yeast the strategy has been exploited in expanding antibody diversity [21, 22]. In this study, we further explore the use of plasma cells as a blueprint for the development of a *S. cerevisiae* antibody factory by co-expressing a comprehensive set of mammalian derived ER folding factors together with a full-length IgG in yeast. We screened constructs for expression of ten folding factors shown to interact with nascent antibodies in their endogenous environment and identified elements beneficial for improving IgG titers in yeast. We show that the improvements of the engineered strains were specific for recombinant mammalian proteins, as the effects were similar with human erythropoietin but absent in expression of the endogenous yeast acid phosphatase. Although the yeast PPIase Cpr5p expressing strain generated the highest antibody titers, we demonstrate that mammalian folding factors can successfully be used in engineering of folding in yeast.

2 Materials and methods

Enzymes used for DNA amplification and manipulation were purchased from Thermo Fisher Scientific (Vantaa, Finland). Media components and reagents were obtained from Sigma-Aldrich (Helsinki, Finland) unless stated otherwise.

2.1 Yeast strains

As described in detail in [9], two yeast strains served as the basic chassis in all screening experiments: W303 α and W303 $\alpha\Delta opi1$, from here on referred to as wt and $\Delta opi1$, respectively. Both strains harbor a single copy of the light and heavy chain encoding genes of the monoclonal antibody C2B8 under control of the GAL1-promoter integrated to the genomic *HIS3*-site.

The acid phosphatase gene (*PHO5*) and cDNA for human EPO (Source Bioscience, clone OHu20340) were cloned under P_{GAL1} into the integrative pRS305K-plasmid [23]. P_{GPD}-*PHO5*-*cyc1* cassette from plasmid pAX391 [24] was inserted between SmaI and BssHII sites of the pRS305K-backbone creating plasmid pAX401. P_{GPD} was replaced with a PCR amplified P_{GAL1} promoter (oligonucleotides 28 and 29, Supporting information, Table S1) using exonuclease and ligation independent cloning (ELIC) after BamHI SpeI digestion of the vector [25]. The mat α -leader sequence (Mat α) EPO fusion was assembled in two consecutive steps in plasmid pSL1180. PCR amplified Mat α (oligonucleotides 32 and 33) and EPO (oligonucleotides 30 and 31) were digested with BamHI NheI and NheI HindIII, respectively and inserted into pSL1180. The Mat α -EPO fusion was excised and inserted into BamHI HindIII sites of pRS426-GAL1 [26]. The P_{GAL1}-EPO expression cassette was amplified with oligonucleotides 27 and 28 and inserted into BamHI and XhoI digested pAX401 with ELIC, replacing the promoter and ORF before the *CYC1*-terminator. The resulting plasmids were linearized with either Eco31I or AatII and introduced into the *LEU2* locus of both wt and $\Delta opi1$.

2.2 Cloning the plasmid library

cDNAs encoding human ERdj3, mouse GRP94, and human GRP170 were obtained from Dr. Linda M. Hendershot, while human ERp57 cDNA was received from Dr. Kari Kivirikko. Dr. Lloyd Ruddock provided coding regions for human FKBP2, cyclophilin B, P5 L20-L440 and ERp72. Human PDI cDNA was from Dr. Neil Bulleid. cDNA for human BiP was obtained from Source Bioscience (IMAGE clone 5020098). The used oligonucleotides are presented in Supporting information, Table S1.

The selected cDNAs were cloned into the low-copy number yeast shuttle vectors pRS415 and pRS416 [26] under GAL1 (P_{GAL1}), GPD (P_{GPD}), and TEF (P_{TEF}) promoters and under the UPR-controlled promoters derived from the *PDII* (P_{PDII}) and *KAR2* (P_{KAR2}) genes, as described in [9]. Native ER targeting signals were used for all genes except P5, which had the leader peptide from yeast PDI [25]. Oligonucleotides 1 and 2 were used to amplify cDNA for human BiP replacing the human ER retrieval sequence with the yeast sequence. Vectors and insert were both digested with SpeI and XhoI and T4 ligase was used for fragment ligations generating plasmids with BiP under control of P_{GAL1} , P_{GPD} , and P_{TEF} . The ERdj3 insert was amplified with oligonucleotides 3 and 4 so that the fragment ends contained Eco31I sites. The oligonucleotides were designed so that after digestion of the insert with Eco31I the sticky ends became compatible with SpeI and XhoI sites, which were used to cut the vectors.

The cloning of P5 and GRP94 to pRS41X-vectors is described in [25]. Other cDNAs were cloned into pRS41X-vectors using ELIC [25]: the cDNAs were amplified in the first round of PCR with gene specific oligonucleotides. An adaptor sequence of 16 bp was added to the 5' end. The yeast specific ER retrieval signal (HDEL) was either mutated in the original gene sequence (GRP94, PDI, GRP170, P5, BiP), or inserted at the C-terminal end of the genes (ERdj3, ERp57, ERp72,

FKBP2, CypB). If HDEL resulted from mutation, the first round of PCR introduced a 17 bp adaptor sequence to the 3' end. In case of HDEL insertion, an additional round of PCR was used to add the 3' adaptor sequence by using gene specific 5' oligonucleotide and oligonucleotide number 19 to add the adaptor sequence to 3' end. The last round of PCR introduced complementary ends to the plasmids (adaptor specific oligonucleotides number 20 and 21-25). BiP cDNA was introduced under P_{KAR2} and P_{PDI} by amplifying the gene with oligonucleotides 26 and 27 thus adding the adaptor sequence only to the 5' end. All amplified coding sequences were cloned into linearized vectors with ELIC [25]. The destination vectors were linearized with SpeI and XhoI as above, except for plasmids containing P_{KAR2} where XbaI and XhoI were used. Plasmids were transformed into the yeast strains using the lithium-acetate method [27]. Control strains contained only the empty vectors to complement the auxotrophies.

2.3 Screening process and cultivation of yeast strains

Screening the yeast strains was conducted in deep-well plate format as outlined in [9]. Briefly, the saturated pre-cultures of OD₆₀₀ between 5 and 10 were diluted 1:4 in fresh SD-URA-LEU media, which contained 2 % raffinose, and grown at 30 °C, 250 rpm for 5.5 hours before protein expression was induced by adding galactose to a final concentration of 0.5 or 2 %. Protein expression was continued for 24 hours at 20, 25, or 30 °C, 250 rpm. OD₆₀₀ was measured with an Eon Microplate Spectrophotometer (BioTek, Winooski, USA). Samples for ELISA were clarified by centrifugation, adjusted to 1xPBT (135 mM NaCl, 2.5 mM KCl, 10 mM Na₂HPO₄, 1.75 mM KH₂PO₄ with 0.05 % Tween-20) and stored at -20 °C until analysis. Each strain was cultivated in at least three biological replicates.

Cultivations of EPO and acid phosphatase expressing strains were conducted as described for the screening process but protein expression was performed only at 30 °C, 250 rpm. Samples were

prepared from three biological replicates, using two technical replicates for each. Acid phosphatase activity assay was conducted immediately after the cultivations. Culture supernatants of EPO cultures were clarified by centrifugation and stored at -20 °C until analysis.

2.4 Quantification of IgG and EPO titers and acid phosphatase activity

Antibody titers were determined in duplicate measurements with ELISA as specified in [28]. Data was analyzed by using Gen5 (BioTek Winooski, USA) and R software. Statistical analyses were conducted as described in [9].

The acid phosphatase assay was conducted as described in [24], with the exception that the assay was done at 22 °C. The substrate, 20 mM para-nitrophenyl- phosphate in sodium acetate buffer pH 4.2, was added to start the reaction. Reaction was terminated after 0, 2, 10, and 20 minutes and absorbance was read at 405 nm with BioTek Synergy 2 spectrophotometer. Relative acid phosphatase activity was determined from the colorimetric product formation as the slope of absorbance versus time. Concentration of EPO was determined with a commercial ELISA-kit (RAB0654, Sigma Aldrich) following the manufacturer's instructions. Absorbance at 450 nm was read with BioTek Synergy 2 spectrophotometer.

2.5 Shake flask cultivations

Strains were inoculated to 5 ml SD-URA-LEU with 2 % glucose and grown overnight at 30 °C, 250 rpm to OD₆₀₀ 5-10. Ten OD₆₀₀ of cells were collected by centrifugation at 3,000 g for 5 minutes and the cell pellet was resuspended in 10 ml of expression media (SD-URA-LEU with 2 % galactose) obtaining a starting OD₆₀₀ of 1.0. Strains were cultivated in 250 ml shake flasks in inducing conditions at 30 °C, 200 rpm for 24 hours and samples were collected at time points 0, 6, 12, and 24 hours. Supernatant samples were collected as follows: 1 or 2 ml was taken from culture, cells were spun down and the supernatant was adjusted to 1xPBT and stored at -20 °C until

analysis. Resulting cell pellets were resuspended in the same volume of fresh, prewarmed media and returned to the expression culture. Sample collection resulted in culture media replacement at a rate of 1 ml per six hours. OD₆₀₀ was measured with an eppendorf Biophotometer plus – spectrophotometer (Eppendorf AG, Hamburg, Germany). IgG titers were measured in 2-3 technical replicates as described in [28]. All shake flask cultures were repeated with three biological replicates. To account for the dilution due to addition of fresh media, averaged volumetric productivity P_{avg} (ngml⁻¹h⁻¹) was defined as

$$P_{avg} = \frac{[AB]_2 V - [AB]_1 (V - V_s)}{V(t_2 - t_1)}$$

Where $[AB]_2$ is the measured antibody titer, $[AB]_1$ is the antibody titer of the previous time point, V is the culture volume, V_s is the sample volume taken in the previous time point and t_2 and t_1 are the time points in hours.

3 Results

3.1 Selected mammalian folding factors were overexpressed in two chassis strains and showed an increase in specific product yields with increasing temperature

Guided by studies on plasma cell differentiation and IgG folding, we selected a subset of ER resident folding factors known to be involved in IgG synthesis and folding [29]. We selected two PPIases, FKBP2 and cyclophilin B (CypB), four PDIs (P5, ERp57, ERp72, and PDI), the chaperones BiP and GRP94, and the co-chaperones of BiP, ERdj3 and GRP170. GRP170 has also been reported to have holdase activity, as it binds unfolded proteins directly [30]. All the selected genes are significantly upregulated both at protein and transcript level after four days of B cell differentiation (Supporting information, Table S3), as we concluded from our own analysis of microarray data published in [31] and proteomics data reported in [14]. To be able to adjust expression levels of the folding factors, the selected mammalian cDNAs were expressed under control of five different promoters. In order to allow co-expression, the expression constructs were cloned into plasmids with *LEU2* and *URA3* selection markers resulting in 65 different plasmids (Supporting information, Table S2).

The plasmids were transformed individually and in combinations into two different IgG producing strains, the nonengineered wt and the $\Delta opil$ strain, containing the deletion of the *OPH1*-gene that results in an enlarged ER and significantly higher IgG secretion [9, 32]. To determine the specific product yields of our strains, we used a previously established screening platform described in [9]. We cultivated all strains at 20, 25, and 30 °C using 0.5% and 2.0% galactose for induction. Specific product yields (IgG titer normalized by cell density) increased with temperature while the wt and $\Delta opil$ strains remained as two distinct populations (Supporting information, Fig. S1). Generally, IgG titers and specific product yields were higher with 0.5 % than with 2 % induction, although

the difference in specific product yields was smaller than in titers between the two induction levels (Supporting information, Table S4, S5).

3.2 PPIases and the chaperone BiP with its co-chaperone GRP170 were the most successful folding factors to improve specific product yields

In order to identify constructs capable of improving specific product yields, we took the overall performance of the strains with both induction levels into account. By first comparing the strains to the respective background strain within a condition (Supporting information, Table S4), we determined the mean fold-change in specific product yield for each construct, as shown in Fig. 1A. The corresponding IgG titer distributions are shown in Fig. 1B for wt and in Fig. 1C for *Δopi1* strains. In most cases, expression of folding factors resulted in relatively minor effects, and did not change the specific product yields considerably (Fig. 1A). Neither the different molecular functions of proteins nor the promoters allowed separating the tested strains into different groups, indicating that the effect of overexpression of different folding factors remained largely unpredictable. Based on the results from the screening approach, we identified the PPIases FKBP2 and CypB, BiP and its co-chaperone GRP170 as the most interesting candidates, which improved specific product yields up to 1.6-fold. Interestingly, the strains with the co-chaperone performed slightly better than those with BiP (Fig. 1A). In the *Δopi1* strains, the UPR-controlled promoters P_{KAR2} and P_{PDH} seemed to produce the best level of chaperone expression (Fig. 1A, right panel). This is in line with our previous observation that these promoters are useful modules in adjusting overexpression of chaperones [9]. In contrast, stronger promoters were responsible for the highest fold-changes in wt strains (Fig. 1A, left panel), demonstrating that a different level and pattern of expression was required in these two strain backgrounds.

Although the highest fold changes were observed at 25 °C, the highest IgG titers were observed at 30 °C (Supporting information, Table S4).

The results in Figure 1 show one clear deviation: the wt strain expressing P5 under control of P_{GAL1} performed extraordinarily well in antibody secretion. All the measured specific product yields of this strain were above 1.5 –fold, in lower temperatures up to 3.6 –fold (Fig. 1A, Supporting information, Table S4). This strain also had the highest mean IgG titer from all wt samples (Supporting information, Table S4).

3.3 Co-overexpression of two folding factors revealed limited benefits of several modifications to ER and folding

Based on the reported interactions of the different folding factors [33] depicted in Fig. 2A, we tested all the shown pairs of genes and determined their effect on antibody titers (Fig. 2B). We selected one or two promoters for each folding factor based on the screening results obtained with the single construct cultivations. In total, we tested 35 different combinations (Supporting information, Table S5). For the wt strains, we observed a small shift towards higher antibody titers upon co-expression of two folding factors (Fig. 2B lower panel compared to Fig. 1B). In contrast, *Δopi1* strains co-expressing two folding factors hardly exceeded the improvement obtained by the *OPI1*-deletion alone (Fig. 2B). Generally, the overexpression of a second folding factor in a strain that had already displayed high specific product yield did not result in an additional benefit.

The best strains of the two screening sets are summarized in Table 1, which shows the highest overall specific product yields from both strain backgrounds. In the best producing *Δopi1* strains, all folding factors were expressed under control of P_{KAR2} and P_{PDH1}. Combined with the *OPI1*-gene deletion, GRP170 overexpression led up to 6-fold higher specific product yield compared to

the wt (Table 1). Although the improvement in specific product yield was smaller, the *Δopi1* strains expressing FKBP2 or BiP under P_{PDI} reached comparable titers to GRP170 overexpression strain, being slightly over 100 μg/l (Table 1). None of the strains with simultaneous overexpression of two folding factors was among the ten best strains in the *Δopi1* background. In contrast, four of such pairs in the wt background are listed in Table 1. In addition, the folding factors improving specific product yields in *Δopi1* background were noted to be more effective when expressed under stronger promoters in wt (Table 1). It is possible that deletion of *OPI1* gene already enables the cell to circumvent major portion of the folding bottleneck, whereas the demand for improvement in wt strains is larger and requires a greater amount of folding factors.

3.4 Folding factor overexpression affected only mammalian protein secretion

Our main assumption was that the folding factors would improve secreted antibody titers through increasing the folding rate of IgG in the yeast ER, but other cellular effects of folding factor overexpression cannot be excluded. In the case of BiP, we investigated the interaction of this protein with intracellular antibody by co-immunoprecipitation, and confirmed that the antibody interacts with human BiP in the yeast cell (Supporting information, Fig. S2). For most other folding factors, we verified their co-expression in yeast and interestingly, their expression levels varied considerably even when expressed under the same promoter (Supporting information, Fig. S3). To determine if the folding factors had a general influence on protein production, we tested for their possible effects on the secretion of two additional model proteins. We created strains with and without the *OPI1*-gene deletion that had an overexpression cassette of the endogenous yeast protein, Pho5p, a secreted acid phosphatase, or of human erythropoietin (EPO), a heavily glycosylated cytokine. Acid phosphatase activities and EPO concentrations were recorded after

cultivation in the same conditions as for the IgG titer measurements at 30 °C (Table 1). Although the *OPII*-gene deletion increased IgG titers significantly, it halved the amount of secreted acid phosphatase activity in the supernatant (Fig. 3A). Some of the most interesting folding factor constructs were tested together with Pho5p overexpression (P5, the GRP94/ERp72 pair, BiP, GRP170, and FKBP2, constructs from strains 87, 306, 151, 142 and 124, see Table 1), but they had little effect on Pho5p production (Fig. 3A). Moreover, in contrast to IgG, the differences in induction strength had a clear impact on Pho5p activity; 2 % galactose at least doubled the activity of Pho5p in the supernatant (Fig. 3A). Overall, the secretion patterns of acid phosphatase and IgG were completely different in the strains tested. When testing expression of EPO, the improvements in the production of this cytokine followed the same trends as observed for IgG secretion (Figure 3B). In addition to the titers shown in Figure 3B, also patterns in specific product yields were comparable with IgG and EPO (data not shown). Overall, the effects of the beneficial modifications identified here seemed to be specific only for the two mammalian glycoproteins tested (Figure 3). Interestingly, increasing induction hampered EPO secretion more than measured for IgG (Figure 3B). As secretion of Pho5p could simply be increased with stronger induction, this demonstrates that the secretory pathway is more adapted for the expression of the endogenous protein Pho5p than for IgG and EPO.

3.5 Mammalian PPIase FKBP2 displayed similar improvements to the yeast PPIase CPR5

We cultivated a selection of strains in shake flasks and followed the production over time to gain more insight into the secretion behavior of these strains. We chose strains expressing BiP, FKBP2, and GRP170 from the *Δopi1* strains (numbers 142, 124 and 151), and the strains expressing P5, and the GRP94/ERp72 pair (numbers 87, and 306) from the wt background, as these resulted in the highest improvements in specific product yield in the two backgrounds (Table 1). Secretion

1 phenotypes of these strains were confirmed in shake flask cultivations, as the IgG titers were
2 comparable to the screening cultures (Fig. 4A, 4B). We previously reported a yeast PPIase
3 construct, P_{GPD} -*CPR5*, which strongly increased specific antibody yields [9]. As we wanted to
4 compare the two approaches of having a native versus a heterologous folding enhancer, we
5 included this Δ *opi1* -based strain expressing the native ER localized PPIase in this experiment.
6 Although the Cpr5p-overexpression strain reached the highest titer at 24 hours, the mammalian
7 PPIase FKBP2 expressing strain produced similar titers in a shorter time (Fig. 4B). When we
8 plotted averaged volumetric productivity against OD₆₀₀, we noticed that the increase in
9 productivity was accompanied with a shift to lower cell densities, especially in the Δ *opi1* strains,
10 indicating that high titers were achieved at the expense of culture density (Fig. 4C, 4D). Thus,
11 although the increase in specific product yield was much greater with overexpression of Cpr5p
12 ([9]) than for FKBP2 (Table 1), the difference in IgG titer at 24 hours was relatively small.
13 Overexpression of folding factors seemed to improve volumetric productivity especially around
14 the midpoint of the cultivations (Fig. 4C, 4D). In the wt background, the folding factor expressions
15 actually decreased productivity during the first six hours (Fig. 4C). Afterwards, the cells seem to
16 adapt to the production phase, as the productivity strongly increases (Fig. 4C). Interestingly, in the
17 shake flasks, most of the strains reach their maximum IgG titer already at 12 hours after induction
18 (Fig. 4A, 4B). In accordance to other studies [10], protein degradation might be a prevalent
19 problem in our yeast system, as the productivity turned to negative values at the last time point
20 (Fig. 4C, 4D).

4 Discussion

Improving folding and secretion of recombinant proteins is a complicated task as the effects of overexpressing folding factors are not straightforward to anticipate and dependent on the target recombinant protein [18, 34]. In contrast to upregulating endogenous folding factors, in this study we explored an alternative approach for folding engineering: we looked at the native environment of the target protein and transferred the antibody-specific folding factors to the selected host. The folding helpers we selected represent each of the different classes of folding factors that interact with the folding heavy and light chain polypeptides [35]. Judging by the reported abundance of interactions with the IgG molecule, human BiP would be the first choice to transfer as a folding enhancer [29]. Although not as successful in shake flasks, co-expression of human BiP was improving the specific product yields of IgG up to 1.5-fold (Table 1), more than overexpression of the yeast equivalent Kar2p [9, 36]. The PPIase FKBP2 and the chaperone GRP170 were also effective in improving titers, resulting in an up to 6-fold increase in specific product yields when combined with the deletion of *OPH1*-gene (Table 1, Fig. 4B). GRP170 is a homolog of yeast co-chaperone Lhs1p, but the beneficial effects of GRP170 are most likely to rise from its activity to bind unfolded proteins directly [30]. Although improvements were achieved, the antibody- and plasma cell inspired engineering approach yielded similar results to the host-specific approach. In both cases, the most striking observation was the criticality of the expression levels of the folding factors (Figure 1A, [9]). Fine-tuning the expression levels with the selection of promoters did not display much predictability, and the same promoter did not guarantee similar protein levels (Fig. 1A, Supporting information, Figure S3). In addition, the combination of folding factors were generally not improving IgG titers to the same extent (Fig. 2B), probably due to the overload from

multiple protein overexpression. For future approaches of ER engineering, the selection of promoters should be broadened, mainly to weaker promoters.

PPIases present an intriguing class of factors to improve antibody folding, as specific peptidyl prolyl-isomerizations have been reported to constitute the rate-limiting steps in immunoglobulin fold formation and IgG tetramer assembly [37–39]. In fact, all antibody domains require at least one *cis* configured proline residue [29]. Lilie et al. [37] reported that the isomerization of Pro159 might have been responsible for slow folding of a Fab fragment, which would correspond to Pro157 in our heavy chain. This proline is located in the C_H1 domain that is key in the control of IgG assembly [39]. Under normal conditions, ER-specific PPIase activity in *S. cerevisiae* is barely needed [40], so upregulating PPIase activity seems to be crucial for improving IgG titers in yeast. The two mammalian PPIases CypB and FKBP2 were both successful in improving specific product yields and IgG titers (Table 1, Figure 4), although not to the same extent as the yeast PPIase Cpr5p (Figure 4B). It is possible that Cpr5p acts on several of the proline residues, while it has been shown for CypB and FKBP2 that they have differential substrate specificity limited to certain peptidyl-prolyl isomerizations of antibodies [37].

Although we demonstrated that at least BiP interacts with IgG in yeast (Supporting information, Figure S2), the effects of the constructs might partially results from pleiotropic effects. For example, the wt strain Y87 with P_{GAL}-P5 expression cassette was an outlier in our screening experiments (Figure 1A). P5 was the only folding factor that was expressed with a yeast-derived leader peptide, and interestingly, the folding factor showed significant effects only when expressed under P_{GAL1}. A possible scenario for a pleiotropic effect would be the overload of the translocation machinery. Perhaps the yeast-derived leader peptide in combination with a strongly induced promoter resulted in P5, light and heavy chains competing with each other for availability of

translocation machinery. Overloading the translocation step might explain the initial decrease in productivity in the wt-based strains expressing P5, or the GPR94/ERp72 pair (Fig. 4A, 4C). If translocation is initially slowed down, the passing heavy and light chains might have more space available in the ER to assemble and exit while overloading of ER is circumvented. Transit through the ER has been shown to determine the limits of secretion capacity [41], so effectively reducing the translocation rates of target proteins might prevent protein accumulation and lead to increase in secretion. Clearly, events related to the ER seem to be most crucial in determining the speed of IgG secretion and are likely rate limiting also for secretion of the other mammalian recombinant glycoprotein tested, EPO (Figure 3B).

Co-overexpressing mammalian folding factors together with human antibodies proved to be an interesting alternative to engineering the yeast host for improved IgG secretion, although the native folding factor Cpr5p remained superior to heterologous folding factors. Nevertheless, several of the mammalian proteins were successful in improving titers and it would be interesting to determine how these improvements transfer to the fermentation scale. In any case, our antibody titers of up to 100 µg/l are very modest compared to the commercially employed mammalian cell lines, working with titers up to g/l scale [42]. Use of the IgG's native folding helpers could display better transferability between production systems, so our approach could be adopted for engineering other expression hosts as well. For example, glycoengineered *Pichia pastoris* strain have already demonstrated commercial potential in producing therapeutic antibodies [43]; this yeast might benefit from co-expression of mammalian folding factors. Creating a superior antibody producer requires optimization at the whole cell level and benefits from both IgG and host specific engineering approaches.

1 **Acknowledgement**

2 The study was supported by Aalto University Bioeconomy facilities and Aalto University School
3 of Chemical Engineering. EV Koskela is a recipient of a doctoral study grant from the School of
4 Chemical Engineering, Aalto University. We thank Dr. Linda M. Hendershot, Dr. Kari Kivirikko,
5 Dr. Lloyd Ruddock, and Dr. Neil Bulleid for kindly providing requested cDNAs.

6 EK carried out the molecular cloning work, performed the screening experiments, carried out the
7 interaction study, carried out the statistical analyses, and drafted the manuscript. JR contributed to
8 the screening experiments and the cloning work, and helped to draft the manuscript. AF conceived
9 the study, participated in its design, and helped to draft the manuscript. All authors read and
10 approved the final manuscript.

11

12 **Conflict of interest**

13 The authors declare no financial or commercial conflict of interest.

5 References

- [1] Buss, N.A.P.S., Henderson, S.J., McFarlane, M., Shenton, J.M., et al., Monoclonal antibody therapeutics: History and future. *Curr. Opin. Pharmacol.* 2012, *12*, 615–622.
- [2] Gasser, B., Mattanovich, D., Antibody production with yeasts and filamentous fungi: on the road to large scale? *Biotechnol. Lett.* 2007, *29*, 201–212.
- [3] Durocher, Y., Butler, M., Expression systems for therapeutic glycoprotein production. *Curr. Opin. Biotechnol.* 2009, *20*, 700–707.
- [4] Frenzel, A., Hust, M., Schirrmann, T., Expression of recombinant antibodies. *Front. Immunol.* 2013, *4*, 217.
- [5] Nasab, F.P., Aebi, M., Bernhard, G., Frey, A.D., A combined system for engineering glycosylation efficiency and glycan structure in *Saccharomyces cerevisiae*. *Appl. Environ. Microbiol.* 2013, *79*, 997–1007.
- [6] Piirainen, M.A., Boer, H., De Ruijter, J.C., Frey, A.D., A dual approach for improving homogeneity of a human-type N-glycan structure in *Saccharomyces cerevisiae*. *Glycoconj. J.* 2016, *33*, 189–199.
- [7] Laukens, B., De Visscher, C., Callewaert, N., Engineering yeast for producing human glycoproteins: where are we now? *Future Microbiol.* 2015, *10*, 21–34.
- [8] Rakestraw, J.A., Sazinsky, S.L., Piatetsi, A., Antipov, E., et al., Directed evolution of a secretory leader for the improved expression of heterologous proteins and full-length antibodies in *Saccharomyces cerevisiae*. *Biotechnol. Bioeng.* 2009, *103*, 1192–201.
- [9] de Ruijter, J.C., Koskela, E. V., Frey, A.D., Enhancing antibody folding and secretion by tailoring the *Saccharomyces cerevisiae* endoplasmic reticulum. *Microb. Cell Fact.* 2016, *15*, 1–18.

- 1 [10] Tyo, K.E.J., Liu, Z., Magnusson, Y., Petranovic, D., et al., Impact of protein uptake and
2 degradation on recombinant protein secretion in yeast. *Appl. Microbiol. Biotechnol.* 2014,
3 98, 7149–7159.
- 4 [11] Ferrer-Miralles, N., Domingo-Espín, J., Corchero, J.L., Vázquez, E., et al., Microbial
5 factories for recombinant pharmaceuticals. *Microb. Cell Fact.* 2009, 8, 17.
- 6 [12] Cenci, S., Sitia, R., Managing and exploiting stress in the antibody factory. *FEBS Lett.*
7 2007, 581, 3652–3657.
- 8 [13] van Anken, E., Romijn, E.P., Maggioni, C., Mezghrani, A., et al., Sequential waves of
9 functionally related proteins are expressed when B cells prepare for antibody secretion.
10 *Immunity* 2003, 18, 243–253.
- 11 [14] Romijn, E.P., Christis, C., Wieffer, M., Gouw, J.W., et al., Expression clustering reveals
12 detailed co-expression patterns of functionally related proteins during B cell
13 differentiation. *Mol. Cell. Proteomics* 2005, 4, 1297–1310.
- 14 [15] Robinson, a S., Hines, V., Wittrup, K.D., Protein disulfide isomerase overexpression
15 increases secretion of foreign proteins in *Saccharomyces cerevisiae*. *Biotechnology. (N.*
16 *Y).* 1994, 12, 381–384.
- 17 [16] Hsu, T.A., Eiden, J.J., Bourgarel, P., Meo, T., et al., Effects of Co-Expressing Chaperone
18 BiP on Functional Antibody Production in the Baculovirus System. *Protein Expr. Purif.*
19 1994, 5, 595–603.
- 20 [17] Hou, J., Tyo, K.E.J., Liu, Z., Petranovic, D., et al., Metabolic engineering of recombinant
21 protein secretion by *Saccharomyces cerevisiae*. *FEMS Yeast Res.* 2012, 12, 491–510.
- 22 [18] Delic, M., Göngrich, R., Mattanovich, D., Gasser, B., Engineering of protein folding and
23 secretion-strategies to overcome bottlenecks for efficient production of recombinant

1 proteins. *Antioxid. Redox Signal.* 2014, *21*, 414–437.

2 [19] Dorner, A.J., Wasley, L.C., Kaufman, R.J., Overexpression of GRP78 mitigates stress
3 induction of glucose regulated proteins and blocks secretion of selective proteins in
4 Chinese hamster ovary cells. *EMBO J.* 1992, *11*, 1563–1571.

5 [20] Shusta, E. V., Raines, R.T., Plückthun, A., Wittrup, K.D., Increasing the secretory
6 capacity of *Saccharomyces cerevisiae* for production of single-chain antibody fragments.
7 *Nat. Biotechnol.* 1998, *16*, 773–777.

8 [21] Dinnis, D.M., James, D.C., Engineering mammalian cell factories for improved
9 recombinant monoclonal antibody production: lessons from nature? *Biotechnol. Bioeng.*
10 2005, *91*, 180–189.

11 [22] Gorlani, a, Hulsik, D.L., Adams, H., Vriend, G., et al., Antibody engineering reveals the
12 important role of J segments in the production efficiency of llama single-domain
13 antibodies in *Saccharomyces cerevisiae*. *Protein Eng. Des. Sel.* 2012, *25*, 39–46.

14 [23] Taxis, C., Knop, M., System of centromeric, episomal, and integrative vectors based on
15 drug resistance markers for *Saccharomyces cerevisiae*. *Biotechniques* 2006, *40*, 73–78.

16 [24] Frey, A.D., Aebi, M., An enzyme-based screening system for the rapid assessment of
17 protein N-glycosylation efficiency in yeast. *Glycobiology* 2015, *25*, 252–257.

18 [25] Koskela, E. V., Frey, A.D., Homologous Recombinatorial Cloning Without the Creation
19 of Single-Stranded Ends: Exonuclease and Ligation-Independent Cloning (ELIC). *Mol.*
20 *Biotechnol.* 2015, *57*, 233–240.

21 [26] Mumberg, D., Müller, R., Funk, M., Yeast vectors for the controlled expression of
22 heterologous proteins in different genetic backgrounds. *Gene* 1995, *156*, 119–122.

23 [27] Gietz, D., St Jean, A., Woods, R. a, Schiestl, R.H., Improved method for high efficiency

- transformation of intact yeast cells. *Nucl Acid Res* 1992, 20, 1425.
- [28] de Ruijter, J.C., Frey, A.D., Analysis of antibody production in *Saccharomyces cerevisiae*: effects of ER protein quality control disruption. *Appl. Microbiol. Biotechnol.* 2015, 99, 9061–9071.
- [29] Feige, M.J., Hendershot, L.M., Buchner, J., How antibodies fold. *Trends Biochem. Sci.* 2010, 35, 189–198.
- [30] Behnke, J., Hendershot, L.M., The large hsp70 grp170 binds to unfolded protein substrates in vivo with a regulation distinct from conventional hsp70s. *J. Biol. Chem.* 2014, 289, 2899–2907.
- [31] Le Gallou, S., Caron, G., Delaloy, C., Rossille, D., et al., IL-2 requirement for human plasma cell generation: coupling differentiation and proliferation by enhancing MAPK-ERK signaling. *J. Immunol.* 2012, 189, 161–173.
- [32] Schuck, S., Prinz, W. a, Thorn, K.S., Voss, C., et al., Membrane expansion alleviates endoplasmic reticulum stress independently of the unfolded protein response. *J. Cell Biol.* 2009, 187, 525–536.
- [33] Jansen, G., Määttänen, P., Denisov, A.Y., Scarffe, L., et al., An interaction map of endoplasmic reticulum chaperones and foldases. *Mol. Cell. Proteomics* 2012, 11, 710–723.
- [34] Idiris, A., Tohda, H., Kumagai, H., Takegawa, K., Engineering of protein secretion in yeast: strategies and impact on protein production. *Appl. Microbiol. Biotechnol.* 2010, 86, 403–417.
- [35] Meunier, L., Usherwood, Y., Chung, K.T., Hendershot, L.M., A subset of chaperones and folding enzymes form multiprotein complexes in endoplasmic reticulum to bind nascent

- proteins. *Mol. Biol. Cell* 2002, 13, 4456–4469.
- [36] Xu, P., Raden, D., Doyle, F.J., Robinson, A.S., Analysis of unfolded protein response during single-chain antibody expression in *Saccharomyces cerevisiae* reveals different roles for BiP and PDI in folding. *Metab. Eng.* 2005, 7, 269–279.
- [37] Lilie, H., Rudolph, R., Buchner, J., Association of antibody chains at different stages of folding: prolyl isomerization occurs after formation of quaternary structure. *J. Mol. Biol.* 1995, 248, 190–201.
- [38] Thies, M.J., Mayer, J., Augustine, J.G., Frederick, C.A., et al., Folding and association of the antibody domain CH3: prolyl isomerization precedes dimerization. *J Mol Biol* 1999, 293, 67–79.
- [39] Feige, M.J., Groscurth, S., Marciniowski, M., Shimizu, Y., et al., An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. *Mol. Cell* 2009, 34, 569–579.
- [40] Delic, M., Valli, M., Graf, A.B., Pfeffer, M., et al., The secretory pathway: Exploring yeast diversity. *FEMS Microbiol. Rev.* 2013, 37, 872–914.
- [41] Love, K.R., Politano, T.J., Panagiotou, V., Jiang, B., et al., Systematic single-cell analysis of pichia pastoris reveals secretory capacity limits productivity. *PLoS One* 2012, 7, 1–11.
- [42] Kunert, R., Reinhart, D., Advances in recombinant antibody manufacturing. *Appl. Microbiol. Biotechnol.* 2016, 100, 3451–3461.
- [43] Ye, J., Ly, J., Watts, K., Hsu, A., et al., Optimization of a glycoengineered *Pichia pastoris* cultivation process for commercial antibody production. *Biotechnol. Prog.* 2011, 27, 1744–1750.

1

2 **Table 1.** *The strains with highest specific product yields in each strain background.*

Rank ^{a)}	Strain number	Added elements	Strain	IgG titer (μg/ml) ^{b)}	OD ₆₀₀ ^{b)}	Specific productivity (μg/ml*OD ₆₀₀) ^{b)}	Relative frequency ^{c)}	P-value ^{d)}	Fold-change relative to wild-type ^{b)}
1	142	GRP170-P _{PDI}	<i>Δopi1</i>	0.1050	0.7227	0.1482	0.1071	0.0127	6.37
2	143	GRP170-P _{KAR2}	<i>Δopi1</i>	0.0966	0.7371	0.1373	0.0714	0.0042	5.89
3	151	BiP-P _{PDI}	<i>Δopi1</i>	0.1031	0.8027	0.1306	0.0714	0.0005	5.58
4	124	FKBP2-P _{PDI}	<i>Δopi1</i>	0.1028	0.8069	0.1295	0.0357	0.0008	5.56
5	127	CypB-P _{KAR2}	<i>Δopi1</i>	0.0958	0.7880	0.1209	0.0179	0.0004	5.17
6	152	BiP-P _{KAR2}	<i>Δopi1</i>	0.0917	0.7873	0.1203	0.0357	0.0056	5.14
7	126	CypB-P _{PDI}	<i>Δopi1</i>	0.0993	0.8571	0.1197	0.0357	0.0396	5.15
8	136	P5-P _{PDI}	<i>Δopi1</i>	0.0897	0.7807	0.1168	0.0179	0.0051	5.05
9	138	ERp72-P _{PDI}	<i>Δopi1</i>	0.0937	0.8453	0.1153	0.0536	0.0144	5.01
10	137	P5-P _{KAR2}	<i>Δopi1</i>	0.0904	0.8013	0.1152	0.0357	0.0274	4.95
35	83	none ^{e)}	<i>Δopi1</i>	0.0792	0.9123	0.0918	0.1071		3.94
1	306	GRP94-P _{PDI} & ERp72-P _{TEF}	wt	0.0462	0.9433	0.0503	0.1579	<0.0001	2.14
2	87	P5-P _{GAL1}	wt	0.0573	1.3133	0.0440	0.1053	<0.0001	1.86
3	69	FKBP2-P _{TEF}	wt	0.0472	1.2333	0.0389	0.0526	0.0001	1.66
4	340	GRP170-P _{TEF} & FKBP2-P _{TEF}	wt	0.0467	1.3007	0.0342	0.0702	0.1074	1.46
5	303	FKBP2-P _{KAR2} & ERp57-P _{PDI}	wt	0.0396	1.1693	0.0339	0.0351	0.0004	1.46
6	68	FKBP2-P _{GPD}	wt	0.0409	1.2633	0.0328	0.0175	0.0017	1.41
7	96	GRP170-P _{GAL1}	wt	0.0385	1.2400	0.0318	0.0000	0.0051	1.36
8	141	GRP170-P _{KAR2}	wt	0.0347	1.0827	0.0316	0.0000	0.1204	1.35
9	129	PDI-P _{KAR2}	wt	0.0349	1.1147	0.0315	0.0000	0.0027	1.36
10	356	PDI-P _{KAR2} & FKBP2-P _{TEF}	wt	0.0403	1.2727	0.0315	0.0702	0.1074	1.36
47	73	none ^{e)}	wt	0.0280	1.2080	0.0235	0.0351		1.00

- 1 a) Ranking based on descending specific product yield within parental strain background.
- 2 b) The mean from 0.5% and 2% induction at 30 °C. Averages were calculated from fold-changes that were first compared to the
- 3 respective wild-type samples. OD₆₀₀-values were measured with a microtiter plate and are not path length corrected: the values are
- 4 proportional in approximately 1:5.5 ratio to measurements with regular path length of 1 cm.
- 5 c) Relative frequency in the 95th percentile of measurements within each parental strain at 30 °C.
- 6 d) Calculated with the nonparametric equivalent of t-test, Wilcoxon signed rank test using the parental strain without added elements as
- 7 the reference.
- 8 e) Values from the parental strains are added for comparison.

Figure legends

Figure 1: *Summary of the effects of the folding factor constructs on specific product yields.* (A) The fold-changes in specific product yields are shown as a heatmap for each construct in the two strain backgrounds and at each cultivation temperature. Fold-changes were normalized to the control in the respective condition and the means of the two induction conditions were used. The corresponding IgG titers are depicted as distribution plots at the three temperatures in (B) for all wt strains and (C) for all *Δopi1* strains. The y-axis is proportional to relative frequency and the range of the measured IgG titers is given in the x-axis. The area under each curve is equal to 1.

Figure 2: *Co-expression of folding factor pairs.* The selected chaperones are shown to interact with each other and their reported primary associations [33] are summarized in (A). All folding factor pairs connected by lines in (A) were tested and the mean fold-changes and distribution of IgG titers of each strain in each condition are shown in (B). Fold-changes were calculated from specific product yields (titer normalized by OD₆₀₀). The corresponding mean antibody titers are shown in the x-axis. Dots indicate wt samples and crosses *Δopi1* samples, and the symbols are colored according to temperature as indicated. The horizontal lines describe the baseline of the fold-changes, one for wt and approximately 4.5 for *Δopi1* alone. The lower panel depicts the range of IgG titers in each temperature, shown as distribution plots, solid lines for wt and dashed lines for *Δopi1* samples. The y-axis is proportional to relative frequency and the range of the measured IgG titers is given in the x-axis. The area under each curve is equal to 1. Each data point represents the mean of at least three biological replicates, each with two technical replicates.

Figure 3: *Modifications leading to high IgG titers improved EPO secretion but had no effect on acid phosphatase titers.* IgG titers were contrasted to (A) secreted acid phosphatase and (B) human EPO secretion in wt, *Δopi1*, and several folding factor overexpression strains. BiP, GRP170, and FKBP2 were expressed under P_{PDI} in the *Δopi1* background, while constructs in the wt strains were P5-P_{GAL1} and the GRP94-P_{PDI}/ERp72-P_{TEF} pair. Protein yields were measured from identical culture conditions, both with 0.5 % and 2 % galactose induction. Acid phosphatase activity is described with arbitrary units. Means of three biological replicates, each with two technical replicates, are shown.

Figure 4: *Adding folding factors improved productivity differentially during the time course.* Antibody titers were measured for strains in wt (A) and *Δopi1* (B) background in four time points. Averaged volumetric productivity was calculated from the previous time point taking into account the dilution due to sample collection. Volumetric productivity is shown as a function of OD₆₀₀ for wt (C) and *Δopi1* (D) strains. Time of the sampling points is indicated. Error bars are omitted for clarity, but the standard deviations are approximately 10-30% for samples with high IgG concentrations, and maximum 0.003 µg/ml for samples near zero. G+E; GRP94-P_{PDI} and ERp72-P_{TEF} pair expression, GRP; GRP170-P_{PDI}. FKBP is referring to FKBP2-P_{PDI} and CPR5 to the yeast PPIase Cpr5p expressed under P_{GPD}. Constructs BiP-P_{PDI} and P5-P_{GAL1} were used for expression of BiP and P5.

1 Figures

2 Figure 1

A

B

1

2 **Figure 2**

1

2 **Figure 3**

3

1

2

3 **Figure 4**